|
|
Article: Clinical Results With AVANT Rotavirus Vaccine Demonstrate Nearly 90% Protection in Young Children.
- Article from:
- PR Newswire
- Article date:
- July 22, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEEDHAM, Mass., July 22 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the publication of the detailed results of a Phase II clinical study of AVANT's investigational rotavirus vaccine in the British medical journal, Lancet. The results of the Phase II efficacy trial suggests that the two-dose oral rotavirus vaccine should be helpful in the prevention of rotavirus disease in young children. The clinical investigators reported that the vaccine provided those treated with nearly 90% protection from disease.
David Bernstein, M.D., the lead investigator at the Cincinnati Children's Hospital Medical Center, in association with his ...